Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 an...
Guardado en:
Autores principales: | Satohiro Matsumoto, Hirosato Mashima |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a50c4d8aa4dc4df286985a54519ff870 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Post-ERCP biliary complications in patients with biliary type sphincter of Oddi dysfunction
por: Hiroyuki Miyatani, et al.
Publicado: (2018) -
MSC therapy for inflammatory bowel disease
por: Mikhail A. Konoplyannikov, et al.
Publicado: (2021) -
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Satoshi Tamura, et al.
Publicado: (2020) -
Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini I, et al.
Publicado: (2020) -
RNA interference-based nanosystems for inflammatory bowel disease therapy
por: Guo J, et al.
Publicado: (2016)